EH12-267: A Pilot Study of Neoadjuvant and Adjuvant mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma
Aims: The purpose of this study is to evaluate whether it is possible to give a combination of chemotherapy drugs known as mFOLFIRINOX (5FU, leucovorin irinotecan, and oxaliplatin) before and after surgery to remove pancreatic cancer. This combination of drugs is an established treatment for pancreatic cancer which has spread to other parts of the body and this study may determine whether using it much earlier in the treatment of this cancer is beneficial. A second purpose is to evaluate the effect this treatment has on pancreatic cancer and on participants' survival.  
Diagnosis: Localized, Resectable Pancreatic Adenocarcinoma 
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH12-267
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

CALGB 80803: Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer
Aims: The purpose of this trial is to learn if there can be improvement in the treatment outcomes for patients with esophageal cancer by using PET/CT scans to determine whether or not a particular chemotherapy regimen is showing any effect on the tumor. The research team is trying to learn if PET/CT results can be used as a way to better direct therapy for the tumor.
Diagnosis: Esophageal Cancer
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH12-342
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

UC12-0033: A genotype-guided dosing study of mFOLFIRINOX in previously untreated patients with advanced gastointestinal malignancies.
Aims: This study is being done to determine whether a certain dose of a chemotherapy drug (irinotecan) can be tolerated as part of a combination of drugs. There is a combination of chemotherapy drugs often used to treat your type of cancer. 5-FU, leucovorin, irinotecan and oxaliplatin; the combination is known as "FOLFIRINOX." FOLFIRINOX is a current regimen used for patients with advanced pancreatic cancer. It was recently shown in a separate clinical trial to increase survival compared to another commonly used drug in pancreatic cancer, gemcitabine. FOLFIRINOX is also a reasonable regimen for patients with other advanced cancers of the gastroinestinal tract, including colon cancer, rectal cancer, esophagus cancer, stomach cancer, gall bladder cancer, bile duct cancer, ampullary cancer, and cancers with an unknown primary location.
Diagnosis: Esophageal Cancer 
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH12-266
Sponsor: University of Chicago
Contact: Interested patients should contact research nurse Tara Flanagan, RN at 847.570.1768
Open to Enrollment: Yes

A021101: Neoadjuvant FOLFIRINOX and Chemoradiationo Followed by Definitive Surgery and Postoperative Gemcitabine for Patients with Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study
Aims: The purpose of this study is to evaluate a treatment program for patients with borderline resectable pancreas cancer. The research time wants to find out what effects, good and bad, chemotherapy and chemoradiation have on the patient's cancer and to see if it allows safe surgery. The tumor is borderline resectable, which means it may or may not be able to be safely and completely removed, due to how close the tumor is to major blood vessels. This study aims to determine if the study's treatment plan of chemotherapy, chemo-radiation therapy, and surgery is feasible in patients with borderline resectable pancreatic cancer.  
Diagnosis: Borderline Resectable Pancreatic Adenocarcinoma
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH13-279
Sponsor: CALGB/ Alliance in Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

N1048: A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality
Aims: The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy using a combination regimen known as FOLOX (the drugs 5-flurouracil (5-FU), oxaliplatin and leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely since 2002 to treat patients with advanced colorectal cancer.
Principal Investigator: Marc Singer, MD
IRB Approval Number: EH12-468
Sponsor: Alliance in Clinical Trials in Oncology
Contact: Interested patients should contact research nurse Karen Ohara, RN at 847.570.1572
Open to Enrollment: Yes

RTOG 1112: Randomized Phase III Study of Sorafenib versus Sterotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Aims: The purpose of this study is to compare the effects of sorafenib alone (the present standard of care treatment) with SBRT followed by sorafenib on you and your liver cancer to find out which is better. In this study, you will get either SBRT followed by sorafenib or the sorafenib alone. 
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH14-009
Sponsor: Radiation Therapy Oncology Group (RTOG)
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

Celgene ABI-007-PANC-003: A Phase 3, Multicenter, Open-label, Randomized Study of nab® Paclitaxel Plus Gemcitabine Alone as Adjunct Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma
Aims: The purpose of this study is to determine whether the addition of nab®-paclitaxel to gemcitabine will help to delay the cancer from coming back after surgery. Gemcitabine is a drug commonly used after pancreatic resection.
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH14-056
Sponsor: Celgene Corporation
Contact: Interested patients should contact research nurse Elita Fine, RN at 847.570.2698
Open to Enrollment: Yes

× Alternate Text